Analyst firms · Leerink Partners · ACHC
Leerink Partners ACHC price target and rating history
Acadia Healthcare Company Inc. (ACHC) · Health Care
Leerink Partners rates Acadia Healthcare Company Inc. (ACHC) Market Perform with a $14 price target, as of its latest action on Dec 3, 2025. It has published 3 rating actions on ACHC since September 2021, including 0 upgrades and 1 downgrade. Across 4 firms with a ACHC price target in the last 12 months, the median target is $22. Leerink Partners's $14 is 36% below that.
- Current rating
- Market Perform
- Price target
- $14
- Median target, all firms
- $22
- Actions on ACHC
- 3
Leerink Partners price target on ACHC
Every Leerink Partners rating on ACHC
- Dec 3, 2025
- Mar 1, 2022
- Sep 27, 2021
How other firms rate ACHC
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Raymond James | Outperform | $39 | Sep 28, 2026 |
| Jefferies | Buy | $30 | Jun 3, 2026 |
| Leerink Partners | Market Perform | $14 | Dec 3, 2025 |
| BofA Securities | Underperform | $13 | Dec 3, 2025 |
Questions about Leerink Partners and ACHC
- What is Leerink Partners's price target for ACHC?
- Leerink Partners's latest stated price target for Acadia Healthcare Company Inc. (ACHC) is $14, from its action on Dec 3, 2025.
- What is Leerink Partners's rating on ACHC?
- Leerink Partners rates ACHC Market Perform, a neutral rating, as of Dec 3, 2025.
- When did Leerink Partners last change its view on ACHC?
- On Dec 3, 2025, Leerink Partners downgrades to Market Perform from Outperform, price target $14.
- How does Leerink Partners's ACHC target compare with other analysts?
- Across 4 firms with a ACHC price target in the last 12 months, the median target is $22. Leerink Partners's $14 is 36% below that.
More ACHC rating histories
All Leerink Partners ratingsACHC news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.